Extended Data Fig. 10: B. xylanisolvens-mediated nicotine degradation negatively correlates with clinical NASH.
From: Gut bacteria alleviate smoking-related NASH by degrading gut nicotine
In 41 smokers with NAFLD, NAFL n = 11, borderline NASH n = 16, definite NASH n = 14. a–c, Relative abundances of B. xylanisolvens associated with steatosis score (a), ballooning score (b), and lobular inflammation (c) in smokers with NAFLD. In 42 non-smokers with NAFLD, including NAFL (n = 11), borderline NASH (n = 14), and definite NASH (n = 17). d, Bacterial taxonomic profiling of the gut microbiota from non-smokers with different NAFLD stages at the species level. e, Relative abundances of B. xylanisolvens associated with different NAFLD stages in non-smokers with NAFLD. f-h, Relative abundances of B. xylanisolvens associated with steatosis score (f), ballooning score (g), and lobular inflammation (h) in non-smokers with NAFLD. i, j, Correlative analysis of B. xylanisolvens with ALT (i) and AST (j). Correlations between variables were assessed by linear regression analysis. Linear correction index R square and P values were calculated. k, Summary diagram illustrating the role of microbial nicotine degradation in ceramide modulation and NAFL-NASH progression. Created with BioRender. Data are the means ± s.e.m. a–c, e–h, Kruskal-Wallis test with Dunn’s test.